In conclusion, our study shows the association of the SMYD3VNTR 3/3 as well as upregulation of SMYD3 serum levels and mRNA expression with HCC development, suggesting that SYMD3 has some potential for the prediction of HCC in HBV patients. Here, SMYD3 is linked to hepatocellular carcinoma.